Acne mRNA vaccine for mild acne
Part of Skin clinical trials.
This trial tests an mRNA vaccine designed to treat mild facial acne. It aims to see if the vaccine is safe and effective at reducing acne lesions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Mild facial acne with 10 to 24 blackheads or whiteheads
- Between 5 to 19 red bumps or pus-filled pimples
- No acne cysts or nodules
- Generally healthy with no serious immune system problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental mRNA vaccine designed to help the immune system fight acne-causing bacteria. It's for adults with moderate or severe facial acne who are otherwise healthy, and it may offer a new way to treat acne beyond typical creams or pills.
This trial studies a new mRNA vaccine to see how safe it is for teenagers with moderate to severe acne. If your teen qualifies, they may receive the vaccine in either a low or high dose, while researchers monitor for side effects.
This study tests a cosmetic product alongside a standard prescription acne treatment for 12 weeks, then a maintenance phase to see if the product helps improve acne and skin appearance.
This early-stage study tests a new drug called TVB-3567, which may help treat acne. It checks the drug's safety and how the body processes it, first in healthy people and then in people with moderate to severe acne.
This study looks at skin swabs and blood samples from people with different levels of acne to better understand the condition. You won't receive any new treatment, but you'll help researchers learn more about acne.
This trial tests skincare products designed for people with sensitive skin who have mild to moderate acne. The goal is to see if they safely and effectively reduce acne without irritating sensitive skin.
Hear when a new Acne trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.